ATENO® — Atenolol 50 mg & 100 mg Film-Coated Tablets
1. Disclaimer
This information is intended for healthcare professionals and for educational and reference purposes only. It does not replace the current locally approved prescribing information, the manufacturer's package leaflet, clinical judgment, or consultation with an appropriately qualified healthcare professional.
We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. Readers are responsible for independently verifying the information before relying on it.
Drug indications, contraindications, dosing recommendations, excipients, storage requirements, packaging and regulatory status may differ between countries and between individual atenolol products. For ATENO® marketed in Egypt, the current Egyptian Drug Authority (EDA)-approved labeling and the information printed on the current package should take precedence whenever they differ from other reference sources.
2. Summary
ATENO® contains atenolol, a relatively selective beta1-adrenergic receptor blocker (cardioselective beta-blocker). It reduces sympathetic stimulation of the heart, thereby lowering heart rate, myocardial contractility and cardiac workload, and can reduce blood pressure and myocardial oxygen demand.
Current public information from EIPICO confirms ATENO® as an atenolol cardiovascular product available as 50 mg and 100 mg film-coated tablets. The Egyptian packs listed by EIPICO contain 20 tablets.
Atenolol remains an established treatment for certain cardiovascular conditions. However, contemporary hypertension guidelines generally do not prefer conventional beta-blockers such as atenolol as first-line therapy for uncomplicated hypertension when there is no additional clinical indication for beta-blockade. Current U.S. guidance identifies thiazide-type diuretics, long-acting dihydropyridine calcium-channel blockers, and ACE inhibitors or ARBs as principal first-line options unless there is a compelling reason to select another agent. Beta-blockers remain particularly useful when conditions such as angina, selected arrhythmias, previous myocardial infarction, or a need for heart-rate control coexist.
3. Brand Name
ATENO®
ATENO® should not be confused with ATENO-C®, which is a separate combination product containing atenolol plus chlorthalidone.
EIPICO currently lists:
- ATENO® 50 mg Film-Coated Tablets.
- ATENO® 100 mg Film-Coated Tablets.
- ATENO-C® 50/25 mg Film-Coated Tablets: atenolol 50 mg + chlorthalidone 25 mg.
- ATENO-C® 100/25 mg Film-Coated Tablets: atenolol 100 mg + chlorthalidone 25 mg.
4. Category
- Pharmacological class: Selective beta-adrenergic receptor blocker; predominantly beta1-selective at therapeutic doses.
- Therapeutic class: Cardiovascular drug; antihypertensive and antianginal agent.
- ATC code: C07AB03 — Atenolol.
- Atenolol has no intrinsic sympathomimetic activity and no clinically relevant membrane-stabilizing activity.
Beta1 selectivity is relative rather than absolute and can diminish as the dose increases.
5. Active Ingredient
Atenolol
Each ATENO® tablet contains either:
- Atenolol 50 mg, or
- Atenolol 100 mg.
The current publicly accessible EIPICO product information confirms these strengths.
The complete current excipient composition of the Egyptian ATENO® formulation should be obtained from the current EDA-approved leaflet or product packaging when information about excipient sensitivity is required.
6. Pharmaceutical Form & Strength
Film-coated tablets for oral administration.
Available strengths confirmed in EIPICO's current product information:
- ATENO® 50 mg Film-Coated Tablets
- ATENO® 100 mg Film-Coated Tablets
Current Egyptian product listings indicate packs of 20 tablets for each strength.
7. Manufacturer & Marketing Authorization Holder
Manufacturer / product company:
Egyptian International Pharmaceutical Industries Company (EIPICO)
Tenth of Ramadan City, Egypt.
EIPICO's official product information identifies ATENO® as one of its cardiovascular products, and the company identifies itself as the Egyptian International Pharmaceutical Industries Company.
The exact current Egyptian marketing-authorization number and any separately designated Marketing Authorization Holder should be verified from the current EDA-approved ATENO® package or leaflet because these details are not displayed in the publicly accessible EIPICO ATENO® product listing.
8. Mechanism of Action
Atenolol selectively antagonizes beta1-adrenergic receptors at usual therapeutic doses, particularly in cardiac tissue.
Its clinically important effects include:
- Reduction in resting and exercise-induced heart rate.
- Reduction in myocardial contractility.
- Reduction in cardiac workload and myocardial oxygen demand.
- Slowing of atrioventricular conduction.
- Suppression of beta1-mediated renin release from the kidney.
These effects contribute to its antihypertensive and antianginal actions, although the precise mechanism responsible for the antihypertensive effect of atenolol is not completely established.
Atenolol does not possess intrinsic sympathomimetic activity and has no significant membrane-stabilizing activity. Beta1 selectivity is not absolute and decreases as the dose or systemic exposure increases; consequently, beta2 blockade and bronchospasm can occur, particularly in susceptible patients.
9. Spectrum of Activity
Not applicable in the antimicrobial sense.
Atenolol is not an antibiotic, antiviral, antifungal or antiparasitic drug and therefore has no antimicrobial spectrum of activity.
Its pharmacological activity is principally directed toward beta1-adrenergic receptors, especially in cardiac tissue, although this selectivity is dose-dependent and is not absolute.
10. Pharmacokinetics
Absorption:
Oral absorption is relatively consistent but incomplete. Approximately 40–50% of an oral dose reaches the systemic circulation. Peak plasma concentrations generally occur approximately 2–4 hours after oral administration.
Distribution:
Atenolol is hydrophilic and penetrates tissues relatively poorly compared with more lipid-soluble beta-blockers. Penetration into brain tissue is low. Plasma protein binding is very low, approximately 3%.
Metabolism:
Atenolol undergoes little clinically significant hepatic metabolism; more than 90% of the absorbed drug reaches the systemic circulation unchanged.
Elimination:
Elimination occurs predominantly through the kidneys. The plasma elimination half-life is approximately 6 hours in patients with normal renal function but can become substantially prolonged in severe renal impairment.
Placental and breast-milk transfer:
Atenolol crosses the placenta and is excreted into human breast milk, where clinically important accumulation may occur, particularly in newborn or premature infants.
11. Indications
The publicly available EIPICO ATENO® listing confirms the product and composition but does not provide a complete current Egyptian indication section. Accordingly, the locally approved ATENO® leaflet should be checked for the exact authorized indications.
Current reference prescribing information for atenolol includes:
- Hypertension.
- Long-term management of angina pectoris.
- Certain cardiac arrhythmias, in product labels where this indication is authorized.
- Management of myocardial infarction, including specified acute-care regimens and/or long-term prophylaxis in some atenolol labels.
For uncomplicated hypertension, atenolol remains capable of lowering blood pressure, but contemporary guidelines generally prefer ACE inhibitors/ARBs, dihydropyridine calcium-channel blockers, and thiazide or thiazide-like diuretics as principal first-line drug classes. Beta-blockers are preferentially used when there is an additional indication such as angina, post-myocardial-infarction therapy, heart-rate control or another appropriate cardiovascular indication.
12. Administration
ATENO® is administered orally. Dosage must be individualized according to indication, heart rate, blood pressure, renal function, concomitant therapy and clinical response.
Hypertension
Dosing should follow the current locally approved ATENO® prescribing information.
Current international atenolol labels differ somewhat regarding the initial dose: some recommend 25 mg initially, whereas others use 50 mg once daily initially. Usual effective maintenance doses are generally within the range of 50–100 mg/day.
If the response to the initial dose is inadequate, the dose may be increased according to the approved product information and clinical response. The full antihypertensive response may require approximately 1–2 weeks.
For hypertension, doses above 100 mg/day generally provide little or no additional antihypertensive benefit.
Some reference SmPCs permit a 25 mg starting dose in selected patients, particularly elderly patients or those with renal impairment; ATENO® itself is publicly listed in 50 mg and 100 mg strengths, so any lower dose must be prescribed using an appropriate formulation or only by tablet division if the specific product is approved for accurate division.
Angina Pectoris
Common contemporary regimens are:
- 50–100 mg/day, or
- 100 mg once daily, or 50 mg twice daily, depending on the approved product information and clinical response.
European/UK reference SmPCs generally consider additional antianginal benefit above 100 mg/day unlikely, although some current U.S. atenolol labels permit doses up to 200 mg once daily in selected patients. The locally approved ATENO® dosage should therefore govern maximum dosing.
Renal Impairment
Because atenolol is predominantly eliminated by the kidneys, dose reduction is required in significant renal impairment.
A commonly referenced dosage framework is:
| Creatinine Clearance | Typical Maximum / Recommended Atenolol Dose |
|---|---|
| >35 mL/min/1.73 m² | Usually no renal dose reduction required |
| 15–35 mL/min/1.73 m² | 50 mg daily |
| <15 mL/min/1.73 m² | 25 mg daily or 50 mg on alternate days, depending on the approved formulation and clinical circumstances |
Patients receiving haemodialysis require individualized post-dialysis dosing and close supervision because marked hypotension may occur. Current reference labels use approximately 25–50 mg following dialysis, with some UK SmPCs specifying 50 mg after each dialysis under hospital supervision.
Important
Treatment should not be stopped abruptly, particularly in patients with known or possible coronary artery disease. When discontinuation is necessary, gradual withdrawal—commonly over approximately 1–2 weeks—is generally recommended under medical supervision.
13. Method of Preparation
No preparation or reconstitution is required.
ATENO® is supplied as a ready-to-use film-coated oral tablet.
The tablet should be taken according to the prescribed dose. Crushing or dividing the tablet should not be assumed to be appropriate unless the specific ATENO® tablet is confirmed by its current manufacturer-approved leaflet or packaging to be suitable for such use.
14. Contraindications
Atenolol should not be used in patients with contraindications including:
- Hypersensitivity to atenolol or relevant formulation components.
- Cardiogenic shock.
- Uncontrolled or overt cardiac failure.
- Marked sinus bradycardia.
- Second- or third-degree atrioventricular block in the absence of appropriate pacing.
- Sick sinus syndrome, where listed by the applicable product information.
- Clinically significant hypotension.
- Untreated pheochromocytoma.
- Metabolic acidosis.
- Severe peripheral arterial circulatory disturbance.
Current international atenolol labels differ somewhat concerning bronchospastic disease. Some SmPCs list severe asthma or severe obstructive pulmonary disease as a contraindication, whereas other labels state that patients with bronchospastic disease should generally avoid beta-blockers but permit cautiously selected use of beta1-selective atenolol when alternatives are unsuitable. The locally approved ATENO® contraindications must therefore be followed.
15. Warnings & Precautions
Abrupt withdrawal
Atenolol should not be suddenly discontinued in patients with coronary artery disease. Abrupt beta-blocker withdrawal can precipitate worsening angina, myocardial infarction or ventricular arrhythmias. Gradual withdrawal and clinical observation are advised.
Bradycardia and conduction disorders
Atenolol lowers heart rate and slows AV conduction. Dose reduction or discontinuation may be necessary if clinically important symptomatic bradycardia develops.
Heart failure
Atenolol is contraindicated in uncontrolled heart failure but may be used cautiously in appropriately stabilized patients when another clinically appropriate indication exists. Atenolol should not be assumed to be interchangeable with the specific beta-blockers that have demonstrated morbidity and mortality benefits in heart failure with reduced ejection fraction (HFrEF).
Bronchospastic disease
Beta1 selectivity is not absolute. Atenolol can increase airway resistance or provoke bronchospasm. Patients with asthma or obstructive airway disease require careful assessment and, where use is considered necessary, close supervision.
Diabetes and hypoglycaemia
Atenolol can mask adrenergic warning symptoms of hypoglycaemia, particularly tachycardia, and beta-blockers may increase the risk or duration of severe hypoglycaemia in susceptible patients.
Thyrotoxicosis
Beta-blockade can mask cardiovascular manifestations of hyperthyroidism/thyrotoxicosis.
Peripheral vascular disease
Atenolol may aggravate peripheral arterial circulatory disorders or Raynaud-type symptoms.
Anaphylaxis
Beta-blockers may increase the severity of allergic reactions and can reduce responsiveness to usual doses of epinephrine used for anaphylaxis.
Prinzmetal/vasospastic angina
Beta-blockade may worsen coronary vasospasm in susceptible patients; use requires particular caution.
Surgery and anaesthesia
The anaesthetist should be informed that the patient is receiving atenolol. Beta-blockade can increase susceptibility to bradycardia and hypotension during anaesthesia. Routine abrupt withdrawal immediately before surgery is not recommended.
Renal impairment
Renal function should be assessed because accumulation occurs as renal clearance declines.
16. Drug Interactions
Clinically important or potentially important interactions include:
- Verapamil and diltiazem: may produce marked bradycardia, AV block, hypotension or deterioration of cardiac function, particularly in patients with conduction disease or ventricular dysfunction.
- Dihydropyridine calcium-channel blockers such as nifedipine: may increase the risk of hypotension and, in patients with latent cardiac insufficiency, may contribute to deterioration of cardiac function.
- Other antiarrhythmics, including amiodarone and Class I agents: additive effects on conduction and myocardial contractility may occur.
- Digoxin and other cardiac glycosides: may further slow AV conduction and heart rate.
- Clonidine: inappropriate withdrawal sequencing can cause severe rebound hypertension. When both are used, changes in treatment require medical supervision.
- Other antihypertensive drugs: additive hypotensive effects can occur.
- Insulin and oral glucose-lowering drugs, particularly sulfonylureas: hypoglycaemia may be intensified and warning tachycardia may be masked.
- NSAIDs, particularly regular use of some agents such as indometacin: may reduce the antihypertensive effect.
- Sympathomimetics such as epinephrine/adrenaline: may antagonize beta-blockade or produce complex cardiovascular responses.
- Catecholamine-depleting drugs such as reserpine: may increase the risk of marked bradycardia or hypotension.
- Anaesthetic agents: may enhance myocardial depression, bradycardia and hypotension.
17. Side Effects
Atenolol is generally well tolerated, but adverse reactions can occur.
Common
- Bradycardia.
- Cold extremities.
- Fatigue.
- Gastrointestinal disturbances such as nausea or other digestive symptoms.
Uncommon
- Sleep disturbances.
- Elevation of liver transaminases.
Rare or less common
- Dizziness or headache.
- Paraesthesia.
- Postural hypotension, occasionally associated with syncope.
- Worsening heart failure.
- Precipitation or worsening of heart block.
- Bronchospasm, particularly in patients with asthma or previous bronchospastic symptoms.
- Dry eyes or visual disturbances.
- Raynaud's phenomenon or worsening intermittent claudication.
- Skin rash, psoriasiform reactions or worsening psoriasis.
- Alopecia.
- Purpura or thrombocytopenia.
- Mood changes, nightmares, confusion, psychosis or hallucinations.
- Dry mouth.
- Sexual dysfunction.
- Hepatic toxicity, including rare cholestatic reactions.
Frequency not reliably established
- Hypersensitivity reactions including urticaria and angioedema.
- Lupus-like syndrome has been reported.
Clinically significant difficulty breathing, syncope, severe bradycardia, facial or airway swelling, severe hypotension or worsening heart failure requires urgent medical assessment.
18. Use in Special Populations
Pregnancy
Atenolol crosses the placenta.
The 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy identify atenolol as an exception among beta-blockers that may otherwise be continued when required during pregnancy and recommend that atenolol be replaced before pregnancy when possible. Atenolol use has been associated with an increased risk of small-for-gestational-age/fetal growth restriction, and fetal or neonatal bradycardia and hypoglycaemia may also occur.
Accordingly, atenolol is not recommended during pregnancy when suitable alternatives are available, particularly for treatment of hypertension.
A patient who becomes pregnant while taking atenolol should not discontinue treatment abruptly. Prompt medical review is required so that maternal cardiovascular risk, indication for beta-blockade and appropriate alternative therapy can be assessed.
Breastfeeding
Atenolol is excreted relatively extensively into human breast milk and is predominantly cleared by the kidneys.
Because neonatal renal clearance is immature, clinically significant accumulation is of greatest concern in newborn and premature infants, and alternative beta-blockers are generally preferred while nursing a newborn or preterm infant or when the mother requires high doses of atenolol.
Reported neonatal effects from substantial exposure include bradycardia, cyanosis and hypothermia.
According to current LactMed information, infants older than approximately 3 months appear to be at relatively low risk of adverse effects from atenolol exposure through breast milk, although individual assessment remains appropriate.
Children
Safety and efficacy have not been adequately established in children in major contemporary reference labeling; routine pediatric use is therefore not recommended unless specifically directed by a specialist and supported by an appropriate indication.
Elderly
Dose selection should be cautious. Renal clearance falls with age, and lower doses may be required, particularly when renal function is reduced.
Renal impairment
Dose reduction is required when renal clearance is significantly impaired; see the Administration section.
Hepatic impairment
Because atenolol undergoes little hepatic metabolism, routine dose adjustment solely for hepatic impairment is generally not required in reference SmPCs, although the patient's overall clinical status must be considered.
19. Storage Conditions
The brand-specific current storage instructions printed on the ATENO® carton and EDA-approved leaflet should be followed.
The publicly accessible current EIPICO ATENO® product listing does not specify its storage temperature.
Storage requirements differ among currently authorized atenolol formulations internationally: for example, some reference products specify storage at or below approximately 25°C and in the original packaging, while another current atenolol SmPC states that no special storage condition is required. A storage temperature from another atenolol product should therefore not automatically be assigned to ATENO®.
Keep all medicines out of the sight and reach of children and do not use tablets after their labeled expiry date.
20. Additional Sections
Packaging
Current EIPICO information lists:
- ATENO® 50 mg: 20 tablets.
- ATENO® 100 mg: 20 tablets.
Monitoring
Depending on the indication and clinical status, monitoring can include:
- Blood pressure.
- Resting heart rate and symptoms of excessive bradycardia.
- Renal function.
- Signs of heart failure.
- ECG where conduction abnormalities or arrhythmias are relevant.
- Blood glucose in diabetic patients or patients at risk of hypoglycaemia.
Overdose
Atenolol overdose is a potentially life-threatening medical emergency. Important manifestations include:
- Severe bradycardia.
- Hypotension.
- AV block.
- Acute heart failure or cardiogenic shock.
- Bronchospasm.
- Hypoglycaemia.
- Reduced consciousness or respiratory impairment in severe cases.
Management requires urgent hospital care with cardiovascular and respiratory monitoring and supportive treatment. Measures may include gastrointestinal decontamination when appropriate, intravenous fluids, atropine for significant bradycardia, glucagon and/or appropriate inotropes or vasopressors, temporary cardiac pacing for refractory conduction disturbance, bronchodilator therapy for bronchospasm and glucose for hypoglycaemia.
Atenolol is sufficiently renally eliminated that haemodialysis can remove clinically relevant amounts of the drug.
Current Hypertension-Treatment Context
Although atenolol effectively lowers blood pressure, contemporary guidelines generally do not select it as routine first-line therapy for uncomplicated hypertension without another indication for beta-blockade.
The 2025 ACC/AHA High Blood Pressure Guideline identifies thiazide-type diuretics, long-acting dihydropyridine calcium-channel blockers, and ACE inhibitors or ARBs as principal first-line pharmacological options unless there is a compelling reason to use another drug class.
Beta-blockers remain important when another indication for beta-blockade exists, such as angina, certain arrhythmias, heart-rate control or selected post-myocardial-infarction situations.
Atenolol and Heart Failure
Beta-blockers have an important role in treatment of heart failure with reduced ejection fraction (HFrEF), but atenolol should not be assumed to be interchangeable with the beta-blockers specifically supported by outcome trials for HFrEF.
The 2026 ESC Heart Failure Guidelines identify bisoprolol, carvedilol and sustained-release metoprolol succinate as beta-blockers with demonstrated mortality benefit in HFrEF; nebivolol has evidence for reduction of the combined endpoint of death or cardiovascular hospitalization and is also included in ESC treatment tables.
Atenolol is not listed among these evidence-based HFrEF beta-blockers. Therefore, the presence of heart failure alone should not be interpreted as an indication to substitute atenolol for an evidence-based heart-failure beta-blocker.
ATENO® versus ATENO-C®
ATENO® contains atenolol alone.
ATENO-C® contains atenolol plus chlorthalidone 25 mg and has different pharmacological, electrolyte, renal, metabolic, contraindication and monitoring considerations. The products should not be treated as interchangeable solely on the basis of the atenolol strength.
21. Frequently Asked Questions (FAQ)
Q1. Is ATENO® the same medicine as ATENO-C®?
No. ATENO® contains atenolol alone. ATENO-C® combines atenolol with the thiazide-like diuretic chlorthalidone.
Q2. Is atenolol still used to treat hypertension?
Yes. Atenolol lowers blood pressure and remains an approved antihypertensive medicine in many jurisdictions. However, contemporary guidelines generally prefer thiazide-type or thiazide-like diuretics, long-acting dihydropyridine calcium-channel blockers, ACE inhibitors or ARBs as initial treatment for uncomplicated hypertension unless there is another clinical reason for beta-blocker therapy.
Q3. Can ATENO® be stopped suddenly when blood pressure becomes normal?
No. Normal blood pressure during therapy does not mean the underlying condition has disappeared. Atenolol should not be stopped abruptly, particularly in patients with coronary artery disease. Withdrawal should normally be gradual and medically supervised.
Q4. Does atenolol require dose adjustment in kidney disease?
Yes. Atenolol is predominantly eliminated through the kidneys, and significant renal impairment can markedly prolong its elimination. Dose reduction is generally required when creatinine clearance falls below approximately 35 mL/min/1.73 m².
Q5. Can atenolol be used in asthma?
Atenolol is beta1-selective, but that selectivity is incomplete. It can still provoke bronchospasm. Severe asthma is listed as a contraindication in some current atenolol SmPCs, while other labels permit highly cautious use in selected bronchospastic patients when alternatives are unsuitable. The individual patient's respiratory condition and the locally approved labeling must therefore be considered.
Q6. Can atenolol be taken during pregnancy?
Atenolol is not recommended during pregnancy when suitable alternatives are available, particularly for hypertension, because it has been associated with fetal growth restriction and a higher risk of small-for-gestational-age infants.
A pregnant patient already taking atenolol should obtain prompt medical review rather than discontinuing the medicine abruptly.
Q7. Can atenolol be used while breastfeeding?
Atenolol passes into breast milk to a clinically relevant extent. Alternative beta-blockers are generally preferred when breastfeeding a newborn or premature infant, or when high maternal doses are required, because atenolol can accumulate in young infants.
Current LactMed information indicates that infants older than approximately 3 months appear to be at relatively low risk from exposure through breast milk.
Q8. How long does atenolol take to lower blood pressure fully?
A blood-pressure effect begins earlier, but the full antihypertensive response to a stable dose commonly becomes established over approximately 1–2 weeks.
Q9. Does atenolol affect blood sugar?
It can mask important adrenergic warning signs of hypoglycaemia, especially tachycardia, and may increase the risk or duration of severe hypoglycaemia in susceptible patients. Diabetic patients should therefore monitor glucose appropriately.
Q10. Is atenolol one of the standard evidence-based beta-blockers used to improve survival in HFrEF?
No. Beta-blockers are an important component of HFrEF treatment, but the beta-blockers with specific contemporary outcome evidence include bisoprolol, carvedilol and sustained-release metoprolol succinate, with nebivolol also included in ESC guidance based on its clinical-trial evidence. Atenolol should not be automatically substituted for these agents in HFrEF.
22. References
- Egyptian International Pharmaceutical Industries Company (EIPICO) — Official Registered Products Information. Current public EIPICO product information listing ATENO® 50 mg and 100 mg tablets, each containing atenolol and supplied in 20-tablet packs.
- EIPICO — ATENO® Registered Product Information. Egyptian International Pharmaceutical Industries Company, Tenth of Ramadan City, Egypt.
- Atenolol 50 mg Tablets — Summary of Product Characteristics (SmPC), electronic Medicines Compendium (emc). Updated February 2026. Current information on indications, dosing, contraindications, precautions, interactions, pregnancy, pharmacokinetics and renal impairment.
- Atenolol 100 mg Film-Coated Tablets — Summary of Product Characteristics (SmPC), electronic Medicines Compendium (emc). Current information on atenolol dosage, renal impairment, adverse effects, interactions and pharmacokinetics.
- TENORMIN® / Atenolol — U.S. Prescribing Information, DailyMed, U.S. National Library of Medicine. Current prescribing information regarding hypertension and angina dosing, warnings, renal adjustment, clinical pharmacology and overdose management.
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. American Heart Association / American College of Cardiology, 2025.
- 2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension. European Society of Cardiology.
- 2025 ESC Guidelines for the Management of Cardiovascular Disease and Pregnancy. European Society of Cardiology. Includes updated recommendations regarding beta-blocker use during pregnancy and specific concerns regarding atenolol and fetal growth.
- Drugs and Lactation Database (LactMed®) — Atenolol. U.S. National Library of Medicine, National Center for Biotechnology Information. Last revision December 15, 2025. Includes current information regarding atenolol transfer into breast milk and risk according to infant age.
- 2026 ESC Guidelines for the Management of Heart Failure. European Society of Cardiology. Includes current evidence-based beta-blocker recommendations for heart failure with reduced ejection fraction.
- UK Teratology Information Service / Medicines in Pregnancy — Atenolol. Information regarding atenolol exposure during pregnancy and fetal-growth considerations.
ATENO® is a prescription cardiovascular medicine. Treatment, dose adjustment and discontinuation should be determined by an appropriately qualified healthcare professional according to the patient's cardiovascular status, renal function, concomitant medications and current locally approved prescribing information.